Protara Therapeutics, Inc.
TARA- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001359931
No open-market purchases or sales by Protara Therapeutics, Inc. insiders were filed in the last 90 days; 119 institutions reported holding it in 13F filings for Q2 2026, worth $176.0M in total; no superinvestor holds it.
13F holders, Q1 2022
Institutional positions in Protara Therapeutics, Inc. as of Mar 31, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 35
- −3 vs. Q4 2021
- Shares held
- 6.50M
- −376.9K (−5.5%) vs. Q4 2021
- Total value
- $33.2M
- −$13.3M (−28.6%) vs. Q4 2021
- New holders
- 3
- 8 more added
- Sold out
- 6
- 17 more reduced
Compare with Q4 2021: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting TARA on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 119 | $176.0M |
| Q1 2026 | 114 | $237.4M |
| Q4 2025 | 105 | $212.3M |
| Q3 2025 | 81 | $114.0M |
| Q2 2025 | 76 | $90.1M |
| Q1 2025 | 59 | $123.8M |
| Q4 2024 | 60 | $156.6M |
| Q3 2024 | 35 | $19.1M |
| Q2 2024 | 38 | $22.2M |
| Q1 2024 | 34 | $18.3M |
| Q4 2023 | 30 | $8.17M |
| Q3 2023 | 31 | $8.55M |
| Q2 2023 | 29 | $12.3M |
| Q1 2023 | 29 | $16.9M |
| Q4 2022 | 30 | $14.7M |
| Q3 2022 | 31 | $16.7M |
| Q2 2022 | 33 | $18.4M |
| Q1 2022 | 35 | $33.2M |
| Q4 2021 | 38 | $46.5M |
| Q3 2021 | 36 | $43.7M |
| Q2 2021 | 40 | $69.3M |
| Q1 2021 | 50 | $134.0M |
Institutions, Q1 2022
Shares, value and share of portfolio for each institution holding Protara Therapeutics, Inc.; share changes are against Q4 2021.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| American Portfolios Advisors | 100 | $511 | 0.00% | 00.0% | Unchanged |
| Royal Bank of Canada | 146 | $1.00K | 0.00% | −13−8.2% | Reduced |
| Federated Hermes, Inc. | 426 | $2.00K | 0.00% | +296+227.7% | Added |
| Bank of America Corp | 745 | $3.00K | 0.00% | −6,133−89.2% | Reduced |
| Wells Fargo & Company | 560 | $3.00K | 0.00% | 00.0% | Unchanged |
| UBS Group AG | 574 | $3.00K | 0.00% | +574 | New |
| Barclays PLC | 2,510 | $13.0K | 0.00% | +2,510 | New |
| Morgan Stanley | 6,556 | $33.0K | 0.00% | −21,344−76.5% | Reduced |
| Acadian Asset Management LLC | 11,730 | $59.0K | 0.00% | −5,489−31.9% | Reduced |
| Prelude Capital Management, LLC | 12,872 | $66.0K | 0.00% | −3,983−23.6% | Reduced |
| Susquehanna International Group, LLP | 13,739 | $70.0K | 0.00% | −14,123−50.7% | Reduced |
| Trexquant Investment LP | 16,313 | $83.0K | 0.00% | +1,158+7.6% | Added |
| Bank of New York Mellon Corp | 17,907 | $92.0K | 0.00% | 00.0% | Unchanged |
| Northern Trust Corp | 20,019 | $102.0K | 0.00% | −2,196−9.9% | Reduced |
| Boothbay Fund Management, LLC | 27,591 | $141.0K | 0.00% | 00.0% | Unchanged |
| Dimensional Fund Advisors LP | 30,606 | $156.0K | 0.00% | −2,868−8.6% | Reduced |
| State Street Corp | 30,900 | $158.0K | 0.00% | +1,100+3.7% | Added |
| Renaissance Technologies LLC | 37,600 | $192.0K | 0.00% | −27,200−42.0% | Reduced |
| BlackRock Inc. | 38,916 | $200.0K | 0.00% | −1,224−3.0% | Reduced |
| Assenagon Asset Management S.A. | 43,741 | $224.0K | 0.00% | +43,741 | New |
| Bridgeway Capital Management, LLC | 64,000 | $327.0K | 0.01% | +10,500+19.6% | Added |
| Two Sigma Advisers, LP | 65,918 | $337.0K | 0.00% | −105,000−61.4% | Reduced |
| Millennium Management LLC | 72,350 | $370.0K | 0.00% | −33,895−31.9% | Reduced |
| Geode Capital Management, LLC | 81,964 | $418.0K | 0.00% | +2,947+3.7% | Added |
| Two Sigma Investments, LP | 88,779 | $454.0K | 0.00% | −101,499−53.3% | Reduced |
| Goldman Sachs Group Inc | 152,847 | $781.0K | 0.00% | −44,455−22.5% | Reduced |
| Baker Bros. Advisors LP | 199,671 | $1.02M | 0.01% | 00.0% | Unchanged |
| Boxer Capital, LLC | 209,227 | $1.07M | 0.05% | 00.0% | Unchanged |
| DLD Asset Management, LP | 229,531 | $1.17M | 0.08% | +300+0.1% | Added |
| Ikarian Capital, LLC | 296,426 | $1.51M | 0.46% | +17,170+6.1% | Added |
| Perceptive Advisors LLC | 383,526 | $1.96M | 0.04% | −38,115−9.0% | Reduced |
| Citadel Advisors LLC | 406,248 | $2.08M | 0.00% | −22,118−5.2% | Reduced |
| Vanguard Group Inc | 427,404 | $2.18M | 0.00% | −7,847−1.8% | Reduced |
| OrbiMed Advisors LLC | 830,641 | $4.25M | 0.07% | 00.0% | Unchanged |
| Opaleye Management Inc. | 2,674,031 | $13.7M | 4.24% | +24,031+0.9% | Added |
| Sender Co & Partners, Inc. | 0 | $0 | 0.00% | −28,502−100.0% | Sold out |
| Gyon Technologies Capital Management, LP | 0 | $0 | 0.00% | −12,553−100.0% | Sold out |
| JPMorgan Chase & Co | 0 | $0 | 0.00% | −1,103−100.0% | Sold out |
| Tower Research Capital LLC (TRC) | 0 | $0 | 0.00% | −799−100.0% | Sold out |
| Simplex Trading, LLC | 0 | $0 | 0.00% | −575−100.0% | Sold out |
| Advisor Group Holdings, Inc. | 0 | $0 | 0.00% | −174−100.0% | Sold out |